Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults.
Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials / Fornaro, Michele; Solmi, Marco; Perna, Giampaolo; De Berardis, Domenico; Veronese, Nicola; Orsolini, Laura; Ganança, Licinia; Stubbs, Brendon. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1176-6328. - 12:(2016), p. 1827-36. [10.2147/NDT.S109637]
Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
Fornaro, Michele;
2016
Abstract
Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults.| File | Dimensione | Formato | |
|---|---|---|---|
|
Full-text FINALE.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
469.29 kB
Formato
Adobe PDF
|
469.29 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
